Insider Trading History of Palantoni Frank

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Palantoni Frank since 2006. This trader's CIK number is 1307963. At the time of last reporting, Palantoni Frank was the Director of Lexicon Pharmaceuticals, Inc.. (stock ticker symbol LXRX). Also see all insider trading activities at Lexicon Pharmaceuticals, Inc..

Note that in the past Palantoni Frank also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Lexicon Pharmaceuticals, Inc. (LXRX) by Palantoni Frank

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2023 LXRX 0 $0 0 $0 9,302 $0
2022 LXRX 0 $0 0 $0 4,024 $0
2021 LXRX 0 $0 0 $0 10,638 $0
2020 LXRX 0 $0 0 $0 3,466 $0

Yearly summary of insider trading at Prestige Consumer Healthcare Inc. (PBH) by Palantoni Frank

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2006 PBH 4,780 $49,664 0 $0 0 $0


Insider trading activities at 2 companies by Palantoni Frank:

1. Lexicon Pharmaceuticals, Inc. (LXRX)

2. Prestige Consumer Healthcare Inc. (PBH)

Table 1. Insider trading of Lexicon Pharmaceuticals, Inc. (LXRX) by Palantoni Frank

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2023-05-21 LXRX Option Ex 9,302 .00 0
2022-04-30 LXRX Option Ex 4,024 .00 0
2021-04-24 LXRX Option Ex 10,638 .00 0
2020-04-26 LXRX Option Ex 3,466 .00 0

Table 2. Insider trading of Prestige Consumer Healthcare Inc. (PBH) by Palantoni Frank

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2006-05-19 PBH Buy 2,390 10.39 24,832
2006-05-19 PBH Buy 2,390 10.39 24,832

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Palantoni Frank (Director of Lexicon Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.